Investors :: ProMIS Neurosciences, Inc. (PMN)

Latest News

May 12, 2025

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

View Press Release View All News

March 31, 2025

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 24, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

March 13, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

Latest Presentation

January 27, 2025

Corporate Overview

View Presentation View All Presentations

Upcoming Event

June 12, 2025 10:00 am EDT

2025 Annual Meeting of Stockholders

View Event Add to Calendar View All Events

Latest Financial Results

Q1 2025

Quarter Ended Mar 31, 2025

Earnings Release

10-Q

PDF HTML

XBRL

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Company Overview

ProMIS™ Neurosciences, Inc. (Nasdaq: PMN), is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company has offices in Toronto, Ontario, and Cambridge, Massachusetts.

View Management Team View Board of Directors

Toronto, Canada Office

Address

1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada

Cambridge, MA U.S. Office

Address

Cambridge Innovation Center
1 Broadway
Cambridge, MA 02142
U.S.A.